Trevi Therapeutics (TRVI) Resumen de Acciones
Trevi Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica que desarrolla y comercializa una terapia en fase de investigación para el tratamiento de la tos crónica en pacientes con fibrosis pulmonar idiopática (FPI) y enfermedad pulmonar intersticial sin FPI, y tos crónica refractaria. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 1/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
TRVI Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Trevi Therapeutics, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$13.59 |
| Máximo en las últimas 52 semanas | US$16.12 |
| Mínimo de 52 semanas | US$5.41 |
| Beta | 1.05 |
| Cambio en 1 mes | -6.28% |
| Variación en 3 meses | 13.82% |
| Cambio de 1 año | 108.76% |
| Variación en 3 años | 418.70% |
| Variación en 5 años | 509.42% |
| Variación desde la OPV | 72.24% |
Noticias y actualizaciones recientes
Recent updates
Trevi Therapeutics: Late-Stage Transition Meets Execution Risk
Summary Trevi Therapeutics is transitioning to a late-stage biotech, prioritizing Haduvio for IPF-related chronic cough as its lead indication. TRVI's strong cash position, bolstered by a $150M stock offering, funds operations into 2028 and reduces near-term financing risk. Haduvio's Phase 3 trials in IPF chronic cough, with quantifiable endpoints and safety focus, are the pivotal near-term catalysts for TRVI. Despite a premium valuation (P/B 10.2x–16.3x), TRVI's upside relies on successful late-stage execution; I recommend holding until Phase 3 data. Read the full article on Seeking Alpha
Chronic Cough Trials And Focused Pulmonologist Reach Will Support Long Term Upside Potential
Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio for chronic cough conditions associated with fibrotic lung diseases and refractory chronic cough. What are the underlying business or industry changes driving this perspective?
Chronic Cough Platform And Strong Cash Runway Will Support Future Upside Potential
Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio, an extended release formulation of nalbuphine, for multiple chronic cough indications where there are currently no FDA approved therapies. What are the underlying business or industry changes driving this perspective?We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although...Trevi adds 19% on full data set from mid-stage cough study
Clinical-stage biopharma, Trevi Therapeutics, Inc. (NASDAQ:TRVI) gained 19% pre-market Monday after the company announced complete data from its Phase 2 trial for lead asset Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) U.K.-based CANAL study was designed to compare Haduvio, an oral extended-release formulation of pain therapy nalbuphine, against placebo in terms of the mean daytime cough frequency at Day 22 as the primary endpoint, as measured by an objective cough monitor. The full set of subjects (N=38) reached the primary endpoint with statistical significance indicating a 52.5% change in daytime cough frequency for Haduvio compared to placebo (p<0.0001). The reduction of cough frequency stood at ~76.1% and 25.3% in Haduvio and placebo arms, respectively. The safety profile was in line with data from previous studies for the treatment, and two adverse events were found to be unrelated to the experimental therapy. TRVI expects to start the next trial for this indication in H1 2023. A previous readout from 26 patients in the CANAL trial indicated a 52% placebo-adjusted reduction in daytime cough events for Haduvio.Trevi Therapeutics: Moving Forward
Summary Today, we put Busted IPO Trevi Therapeutics in the spotlight for the first time ever. The company's primary drug candidate Haduvio is moving towards late-stage development as a treatment for prurigo nodularis as well as chronic cough in adults with idiopathic pulmonary fibrosis. An investment analysis follows in the paragraphs below. "It's not unpatriotic to denounce an injustice committed on our behalf, perhaps it's the most patriotic thing we can do."― E.A. Bucchianeri Today, we take our first look at Trevi Therapeutics Inc. (TRVI). The small biopharma firm came public just over three years ago and is deep in Busted IPO territory even with a nice rebound in the shares so far in 2022. What lies ahead for Trevi Therapeutics? An analysis follows below. Seeking Alpha Company Overview Trevi Therapeutics is a clinical-stage biopharmaceutical company based out of New Haven, CT. The company focuses on the development of medicines to treat serious neurologically mediated conditions. Its primary asset in development is Haduvio which is an oral extended-release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. Haduvio has a dual mechanism of action by acting as both an antagonist (blocker) to the body's mu opioid receptor and as an agonist (activator) to the kappa opioid receptor. March Company Presentation This candidate is currently being evaluating for the treatment of prurigo nodularis or PN and chronic cough in adults with idiopathic pulmonary fibrosis or IPF. Chronic cough represents a significant unmet need for IPF patients, as the majority of these patients report this cough as one of their most bothersome aspects of their disease. March Company Presentation Haduvio or Nalbuphine Extended Release [ER] has also been granted Fast Track designation by the FDA for the treatment of itch in patients with prurigo nodularis. In 2011, Endo Pharmaceuticals partnered with Trevi to develop and market compounds incorporating nalbuphine hydrochloride. The stock currently trades just over three bucks a share and sports an approximate market capitalization of $140 million. Pipeline Developments Company Website The stock got a bump in late June 29th when the company disclosed that Haduvio had met key goals in a Phase 2b/3 'PRISM' study for patients with prurigo nodularis. 25% met the primary efficacy endpoint, a clinical measure called 4-point reduction in the Worst Itch - Numerical Rating Scale compared to just 14% of the placebo group. March Company Presentation Patients are currently completing the one-year open-label extension study, which should be over in January. The company is in the process of having an end of Phase 2 meeting with the FDA to discuss the data, next steps and the design for a registrational study that could lead to approval dependent on results. The company would like to do a six-month study with three treatment groups. March Company Presentation Four months before, interim data from a Phase 2 trial evaluating Haduvio to treat IPF suffering from chronic cough found a 52% placebo-adjusted reduction in daytime cough events and the compound was well tolerated. Full results should be out by the end of this quarter. A meeting with the FDA should happen to soon to move this effort to the next stage of development. The company believes this will begin in the first half of 2023. Haduvio could have other potential indications in this category (see above) for other indications. March Company Presentation Analyst Commentary & Balance Sheet Aegis Capital, Oppenheimer and Needham have all reiterated Buy ratings on TRVI over the past four months. All have identical $10 price targets on the stock.Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Rentabilidad de los accionistas
| TRVI | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 0.7% | 5.6% | -3.3% |
| 1Y | 108.8% | 37.6% | 22.3% |
Rentabilidad vs. Industria: TRVI superó a la industria US Pharmaceuticals, que obtuvo un rendimiento del 37.6% el año pasado.
Rentabilidad vs. Mercado: TRVI superó al mercado US, que obtuvo un rendimiento del 22.3% el año pasado.
Volatilidad de los precios
| TRVI volatility | |
|---|---|
| TRVI Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: TRVI no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de TRVI (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2011 | 34 | Jennifer Good | www.trevitherapeutics.com |
Trevi Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica que desarrolla y comercializa una terapia en investigación para el tratamiento de la tos crónica en pacientes con fibrosis pulmonar idiopática (FPI) y enfermedad pulmonar intersticial sin FPI, y tos crónica refractaria. La empresa desarrolla Haduvio, una formulación oral de liberación prolongada de nalbufina, que se encuentra en ensayo clínico de fase 2b Cough Reduction in IPF with nalbuphine ER para el tratamiento de la tos crónica en pacientes con FPI, y en ensayo clínico de fase 2a en pacientes con tos crónica refractaria. Trevi Therapeutics, Inc. tiene un acuerdo de licencia con Keenova Therapeutics plc para desarrollar y comercializar productos que incorporan clorhidrato de nalbufina en diversas formulaciones.
Resumen de fundamentos de Trevi Therapeutics, Inc.
| Estadísticas fundamentales de TRVI | |
|---|---|
| Capitalización bursátil | US$1.92b |
| Beneficios(TTM) | -US$45.61m |
| Ingresos (TTM) | n/a |
¿Está TRVI sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de TRVI | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$45.61m |
| Beneficios | -US$45.61m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.32 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado TRVI a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/09 10:32 |
| Precio de las acciones al final del día | 2026/06/09 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Trevi Therapeutics, Inc. está cubierta por 16 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| William Wood | B. Riley Securities, Inc. |